The safety of high dose continuous propofol infusion in the pediatric intensive care unit at an academic medical center
Die Sicherheit einer hochdosierten kontinuierlichen Propofol-Infusion auf der pädiatrischen Intensivstation eines akademischen Zentrums
Frontiers in Pediatrics · 12.01.2026 · 13
DOI: 10.3389/fped.2025.1718328 ↗Auf einen Blick
In einer retrospektiven Single-Center-Studie an 554 Kindern trat 1 Fall eines Propofol-Infusionssyndroms (0,2 %) auf. Weitere PRIS-assoziierte Ereignisse waren selten.
Fragestellung
Wie ist die Sicherheit kontinuierlicher Propofol-Infusionen bei kritisch kranken Kindern auf der pädiatrischen Intensivstation, auch bei über aktuellen Empfehlungen liegenden Dosen und Dauern?
Methode
Retrospektive Single-Center-Studie in einer nicht-kardialen medizinisch-chirurgischen PICU; Kinder 0–17 Jahre mit Propofol-Infusion ≥12 h und/oder ≥2,4 mg/kg/h; Beobachtung 1/1/2000 bis 9/30/2024.
Ergebnisse
554 Patient:innen; medianes Alter 5,5 Jahre. Propofol: median 3,0 mg/kg/h über 22,8 h. PRIS: 1 Fall (0,2 %); 26 (4,7 %) Todesfälle; Bradykardie 146 (26,4 %), metabolische Azidose 19 (3,4 %).
Schlussfolgerung der Autor:innen
In dieser retrospektiven Single-Center-Studie wurde 1 PRIS-Fall identifiziert. Die Autor:innen betonen, dass dies selten war, aber Wachsamkeit erfordert; Propofol blieb eine mögliche Sedierungsoption.
Kernaussagen
- 1 PRIS-Fall unter 554 Patient:innen (0,2 %)
- Bradykardie bei 146 (26,4 %) und Azidose bei 19 (3,4 %)
- Retrospektive Single-Center-Studie in einer PICU
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pediatrics, online erschienen am 12.01.2026. Verfasst von Oluwatomini A Fashina und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Mayo Clinic Children's, Rochester, MN, United States. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Intensivpflege
Abstract (Originalsprache)
Introduction
Adequate sedation is crucial in the care of critically ill children. Propofol, known for its rapid onset, reliable patient response, and short duration of action, offers an attractive pharmacologic profile. However, concerns for propofol-related infusion syndrome (PRIS) have limited its use in pediatric critical care. This study examined the relationship between propofol administration and PRIS characteristics in a single medical-surgical pediatric intensive care unit (PICU). We hypothesized that continuous propofol infusion, even when judiciously exceeding current recommended doses and durations, is not associated with cardiovascular collapse, metabolic acidosis, or other PRIS-related characteristics.
Methods
This is a retrospective single-center study in the non-cardiac medical/surgical PICU at a tertiary academic medical center of 554 patients. Children aged 0–17 years admitted to the PICU from 1/1/2000 to 9/30/2024, who received propofol infusions for ≥12 h and/or ≥2.4 mg/kg/hour (40 mcg/kg/min) were included. The primary outcome was in-hospital mortality; secondary outcomes included intensive care unit (ICU) length of stay, bradycardia during infusion, and metabolic acidosis during infusion. Data was compared across age groups (<6 months, 6–12 months, 1–5 years, 6–17 years) and medical/surgical diagnosis using the chi-square test for homogeneity and the Kruskal–Wallis tests.
Results
Among 554 patients, the median age was 5.5 (IQR 1.5–12.1) years. The median propofol infusion rate was 3.0 (IQR 1.7–4.2) mg/kg/hour [50 (IQR 28–70) mcg/kg/min], median duration was 22.8 (IQR 16.4–42.4) hours, and median ICU length of stay was 4.7 (IQR 2.0–10.4) days. One case of PRIS was observed (0.2%). There were 26 (4.7%) in-hospital deaths, nonattributable to PRIS. Bradycardia occurred in 146 (26.4%) patients, and 19 (3.4%) patients developed metabolic acidosis.
Discussion
In this single-center retrospective study, one case of PRIS was identified. While rare, its occurrence underscores the need for vigilance. Propofol remains a viable sedation option when used with appropriate monitoring in pediatric critical care.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Mayo Clinic Children's, Rochester, MN, United States.
- Department of Pediatrics, Division of Pediatric Critical Care Medicine, Mayo Clinic Children's, Rochester, MN, United States.
- Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, United States.
- Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, United States.
- Department of Anesthesiology and Perioperative Medicine, Anesthesia Clinical Research Unit, Mayo Clinic Children's, Rochester, MN, United States.
Zitieren
APA
Fashina, O. A., Arteaga, G. M., Crow, S. S., Kashyap, R., Frank, R. D., Khang, X., Andrijasevic, N. M., Bruns, D. L., & Wong Grossman, A. V. (2026). The safety of high dose continuous propofol infusion in the pediatric intensive care unit at an academic medical center. Frontiers in Pediatrics, 13. https://doi.org/10.3389/fped.2025.1718328
Vancouver
Fashina OA, Arteaga GM, Crow SS, Kashyap R, Frank RD, Khang X, et al. The safety of high dose continuous propofol infusion in the pediatric intensive care unit at an academic medical center. Frontiers in Pediatrics. 2026;13. doi:10.3389/fped.2025.1718328
BibTeX
@article{Fashina2026,
author = {Fashina, Oluwatomini A and Arteaga, Grace M and Crow, Sheri S and Kashyap, Rahul and Frank, Ryan D and Khang, Xai and Andrijasevic, Nicole M and Bruns, Danette L and Wong Grossman, Ashley V},
title = {The safety of high dose continuous propofol infusion in the pediatric intensive care unit at an academic medical center},
journal = {Frontiers in Pediatrics},
year = {2026},
volume = {13},
doi = {10.3389/fped.2025.1718328}
}
EUVIMED